Myomo, Inc. Files Registration Statement for Proposed Follow-On Offering
November 13 2017 - 4:05PM
Business Wire
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
commercial stage medical robotics company, announced the filing of
a registration statement with the U.S. Securities and Exchange
Commission (SEC) relating to a proposed underwritten follow-on
public offering of shares of its common stock and accompanying
warrants to purchase common stock.
A registration statement relating to these securities has been
filed with the SEC but has not yet become effective. These
securities may not be sold, nor may offers to buy be accepted,
prior to the time the registration statement becomes effective.
This press release is not an offer for sale of the securities in
the United States or in any other jurisdiction where such offer is
prohibited, and such securities may not be offered or sold in the
United States absent registration or an exemption from registration
under the United States Securities Act of 1933, as amended.
In connection with the proposed offering described above, all
shares held by all officers and directors and certain other
shareholders of the Company became subject to lock-up restrictions
pursuant to agreements entered into with Roth Capital Partners, LLC
(“Roth”). In addition, Tripoint Global Equities, LLC (“Tripoint”)
is releasing, effective November 16, 2017, all of the shares of
common stock subject to lock-up agreements entered into with it in
connection with the Company’s June 2017 initial public offering. As
a result, approximately 59% of shares released from lock-up
restrictions by Tripoint, which includes all of the shares held by
all officers and directors of the Company, will remain subject to
lock-up restrictions pursuant to agreements with Roth.
About MyomoMyomo, Inc. is a commercial stage medical
robotics company that offers expanded mobility for those suffering
from neurological disorders and upper limb paralysis. Myomo
develops and markets the MyoPro product line. MyoPro is a powered
upper limb orthosis designed to restore function to the weakened or
paralyzed arms of patients suffering from CVA stroke, brachial
plexus injury, traumatic brain or spinal cord injury, ALS or other
neuromuscular disease or injury.
Forward Looking StatementsThis press release contains
forward-looking statements regarding the Company's future business
expectations, including statements about the proposed offering,
which are subject to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are only predictions and may differ materially from
actual results due to a variety of factors. Our actual results
could differ materially from those anticipated in these forward
looking statements for many reasons, including, without limitation,
risks related to regulatory approval and market acceptance of our
products, and the other risk factors contained in our filings made
with the Securities and Exchange Commission. More information about
factors that potentially could affect Myomo's financial results is
included in Myomo's filings with the Securities and Exchange
Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only
as of the date made. The Company disclaims any obligation
subsequently to revise any forward-looking statements to reflect
events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171113006270/en/
For Myomo:ir@myomo.comorInvestor Relations:PCG
AdvisoryVivian Cervantes,
646-863-6274vivian@pcgadvisory.comorPublic
Relations:GreenoughRachel Robbins,
617-275-6521rrobbins@greenough.biz
Myomo (AMEX:MYO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Sep 2023 to Sep 2024